Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Importance of Residency Training for the Provision of Comprehensive Clinical Pharmacy Services.

Journal of the American College of Clinical Pharmacy : JACCP·2026

Same author

National trends in prescription drug expenditures and projections for 2026.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Same author

Development of an acuity scoring system to proactively address drug shortages and increase supply chain resiliency.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Same author

ASHP and ASHP Foundation Pharmacy Forecast 2026: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025

Same author

Key partner priorities for measures of safe outpatient paediatric medication use.

BMJ quality & safety·2025

Same author

The Extent and Magnitude of Bias in Case-Crossover Studies of Real-World Non-transient Medications Patterns: A Simulation Study with Real-World Examples.

Drug safety·2025

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Projecting future drug expenditures--2010.

James M Hoffman¹, Fred Doloresco, Lee C Vermeulen

¹Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, TN, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists

|May 21, 2010

Summary

U.S. drug spending grew 1.8% in 2008, reaching $284.7 billion. Projections for 2010 indicate moderate growth, influenced by generic drugs and healthcare reform, with outpatient drug expenditures expected to rise 3-5%.

More Related Videos

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Area of Science:

Health Economics
Pharmaceutical Policy

Background:

U.S. drug expenditures reached $284.7 billion in 2008, a 1.8% increase from 2007.
Growth in clinic drug expenditures slowed to 1.0% in 2008, the lowest in a decade.
Hospital drug expenditures saw a 2.1% increase in 2008 and a 3.0% increase in the first nine months of 2009.

Purpose of the Study:

To analyze drug expenditure trends in 2008 and 2009.
To project drug expenditures for 2010.
To identify factors influencing future drug spending.

Main Methods:

Analysis of historical drug expenditure data (2007-2009).
Forecasting of drug expenditures for 2010.
Identification and discussion of influencing factors.

Main Results:

Total U.S. drug expenditures increased by 1.8% from 2007 to 2008.
Clinic drug expenditure growth was 1.0% in 2008.
Hospital drug expenditure growth was 2.1% in 2008 and 3.0% year-to-date in 2009.

Conclusions:

Projected 2010 outpatient drug expenditures to increase by 3-5%.
Projected 2010 clinic-administered drug expenditures to increase by 6-8%.
Projected 2010 hospital drug expenditures to increase by 2-4%.